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Abstract Addiction is increasingly described as a “chronic and relapsing brain disease”. The potential 
impact of the brain disease model on the treatment of addiction or addicted individuals’ treatment 
behaviour remains uncertain. We conducted a qualitative study to examine: (i) the extent to which 
leading Australian addiction neuroscientists and clinicians accept the brain disease view of addiction; 
and (ii) their views on the likely impacts of this view on addicted individuals’ beliefs and behaviour. 
Thirty-one Australian addiction neuroscientists and clinicians (10 females and 21 males; 16 with clinical 
experience and 15 with no clinical experience) took part in 1 h semi-structured interviews. Most 
addiction neuroscientists and clinicians did not uncritically support the use of brain disease model of 
addiction. Most were cautious about the potential for adverse impacts on individuals’ recovery and 
motivation to enter treatment. While some recognised the possibility that the brain disease model of 
addiction may provide a rationale for addicted persons to seek treatment and motivate behaviour 
change, Australian addiction neuroscientist and clinicians do not assume that messages about “diseased 
brains” will always lead to increased treatment-seeking and reduced drug use. Research is needed on 
how neuroscience research could be used in ways that optimise positive outcomes for addicted 
persons. 
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Introduction 
 
There is a long but unresolved debate about the impact of increasing medicalization of certain 
behaviours, such as mental illness and overeating [1–4]. Special concerns have been raised about the 
medicalization of addiction and its likely impact on the ability of addicted persons to access treatment 
to reduce their drug use and the harm that it causes [e.g. 5, 6]. 
Addiction is increasingly being described by US researchers and the National Institute on Drug Abuse 
(NIDA) as a “chronic and relapsing brain disease” [7– 9]. The evidence cited for this view includes 
research on the genetics of addiction liability and neurobiological changes in the brains of addicted 
animals and humans [e.g. 8, 10]. The American Society of Addiction Medicine (ASAM) has described 
addiction as a “chronic brain disease” [11]. Despite high profile support, the brain disease model (BDM) 
has not been universally accepted [12–14]. 
Advocates of the BDM of addiction believe that its acceptance will have a number of socially desirable 
consequences, namely, increasing public acceptance that addiction is a medical condition, increased 
access to medical treatment for these disorders, and reducing reliance on imprisonment [9, 15]. They 
also argue that it will reduce stigma associated with addiction and thereby increase treatment-seeking 
and improve compliance with treatment [9, 15]. 
There is some support for these claims. Individuals who see addiction as arising from a character flaw 
rather than a medical condition are less likely to seek treatment [16–18]. Similarly, endorsement of 
genetic or neurochemical causes of mental illness, including alcohol dependence, have been associated 
with greater public support for medical treatment and use of medication [19]. By contrast, those who 
believe environmental factors cause mental disorders, including addiction, are more likely to favour 
psychotherapeutic interventions [16, 20, 21]. 
Critics counter that the BDM may adversely affect addicted individuals and the outcomes of addiction 
treatment [12]. Satel, for example, has described the BDM “rhetoric” as “fatalistic”, encouraging 
addicted individuals to believe that they “can never fully free themselves of their drug and alcohol 
problems” [22– 25]. Davies [26] argues that the BDM exculpates the addicted person from taking 
responsibility for their condition: “it’s not me, it’s my disease”. Critics are concerned that biological 
understandings of addiction and other mental disorders may suggest that these disorders are incurable 
[27] or untreatable [28], and will therefore reduce their willingness to seek treatment [29]. 
There is also some evidence to support these criticisms. In a recent survey of public attitudes towards 
the treatability of mental illnesses, those who accepted psychological explanations were more likely to 
see mental illnesses as curable, less debilitating, and less likely to require professional assistance or 
hospitalisation than those who supported biological explanations [30]. Brain-based biological 
explanations also led persons with these disorders to believe that their condition was harder to 
overcome than if they attributed them to psychological causes [30]. If these findings are also true for 
addiction, the BDM could well discourage treatmentseeking or quit attempts. Chapman and MacKenzie 
have argued that a risk of depicting smoking as a brain disease is that smoking will be seen as requiring 
drug-assisted cessation, thereby reducing self-quitting attempts [31]. In contrast, Walker has argued 
that if a person accepts they have a disease that is beyond their control, this may paradoxically 
empower them to seek external assistance rather than rely on personal willpower [32]. 
There has been little empirical assessment of the impact of the strong promotion of the BDM of 
addiction by NIDA, ASAM and others. We conducted qualitative interviews with leading addiction 
neuroscientists and clinicians in Australia to gauge the extent to which these experts accepted the brain 
disease model of addiction. We also explored their views on the likely impacts of the BDM on addicted 
individuals’ beliefs and behaviour. 
 
  
 
Methods 
 
Sample and Recruitment 
 
We recruited 31 Australian addiction neuroscientists and clinicians (10 females and 21 males) using 
expert and quota sampling methods: 48 individuals were contacted with a participation rate of 65 %. 
The average age of the sample was 45 years (ranging from 29 to 65). A database of Australian addiction 
neuroscientists and clinicians (developed by the authors) was used in identifying participants. 
All participants were conducting neuroscience research on addiction in Australia at the time of 
recruitment. The sample was divided into those who had current or past clinical experience in treating 
addicted persons (hereafter clinicians, n=16) and those without clinical experience (hereafter non-
clinicians or neuroscientists only, n=15). The neuroscientists (n=15) included a behaviour geneticist 
(n=1), psychopharmacologists (n=2), human pathologists (n=1), animal researchers (n=7), and cognitive 
neuroscientists/psychologists (n=4). The 16 addiction clinicians included psychiatrists (n=3), clinical 
psychologists (n=11) and physicians (n=2). The majority of the clincians treated persons addicted to 
opioids, alcohol and psychostimulants (n=14). Only two reported treating behavioural addictions, such 
as compulsive overeating. Ethics approval was obtained from The University of Queensland Behavioural 
& Social Sciences Ethical Review Committee. 
 
Qualitative Interviews 
 
Participants took part in a 1-hour semi-structured interview during 2009 and 2010: 26 interviews were 
conducted face-to-face and 5 via telephone. The interview schedule involved open-ended questions 
about participants’ views on addiction aetiology, treatment, research and the impact of addiction 
neuroscience research on policy and the addictions field. These questions were informed by extensive 
research on the ethical and social impact of neuroscience research on addiction by the research group 
[for example see 33, 34]. 
 
Coding 
 
All interviews were transcribed verbatim and coded in QSR NVivo (Doncaster, Australia) version 9 using 
descriptive thematic analysis [see 35]. A detailed coding structure was developed by three members of 
the research team to reflect the primary themes of the interview data. This paper represents a subset of 
these primary themes. Two members of the research group coded data for the primary themes of how 
the BDM of addiction can impact: i) the treatment of addiction and 
ii) addicted individuals’ drug use and treatment behaviour. Data coded within each primary theme was 
then revised to establish secondary themes (see Table 1). 
 
Table 1 Primary and secondary themes emerging from the analysis 
Primary themes  Secondary themes 
1. Treatment of addiction Increased treatment seeking Focus on medical interventions 
Ignore social drivers of addiction 
2. Self understanding & treatment behaviour Facilitates change: positive impacts 
Gain insight or makes sense of one’s condition 
Relieve guilt 
Motivate treatment-seeking 
Empowering 
Hindering change: adverse impacts 
Incurable and learned helplessness 
Undermines self-control and removes responsibility 
3. Endorsement of BDM  
 
Positive  
Negative 
Ambivalent 
 
An iterative approach was used in which new data that challenged the existing coding structure were 
used to revise the secondary themes until no new themes emerged. The third member of the research 
group reviewed coded data to ensure accurate coding and resolved disagreements between the two 
initial coders. 
 
During the analysis process it was noted that many participants highlighted both positive and negative 
influences. The coding structure was later amended to include a global assessment of each participant’s 
views on the impact of BDM. Two authors (AC, SB) independently assessed participants’ overall 
assessment of the impact of BDM of addiction. Participants were classified according to whether they 
thought the impact would be predominantly positive or negative. Participants were coded as positive 
(endorse) or negative (against) if they were unambiguously supportive or critical of the BDM. Those that 
gave both positive and negative responses to the impact of the BDM were coded as “ambivalent”. 
Discrepancies in classification (6 of 31 interviews; agreement rate = 80 %) were resolved to reach a 
consensus assessment. 
 
 
  
Results 
 
The Treatment of Addiction 
 
Most interviewees believed that the BDM could lead to increased treatment-seeking by addicted 
individuals, because a pharmacotherapy may be more appealing than psychological treatments: 
 
“[Addicted individuals] seemed a lot more willing to come forward for [pharmacotherapy] than they 
were when it was just cognitive behaviour therapy … I think that fits into sort of an idea that there 
might be a magic bullet that if you can fix my brain, you’ll fix the addiction” (Cognitive Neuroscientist 1, 
male) 
 
At the same time, this respondent also believed that a focus on medical interventions could be at the 
expense of psychological or behavioural treatments: 
 
“Once you make something a brain disease people tend to think that that makes them less amenable to 
psychological treatments.” (Cognitive Neuroscientist 1, male) 
 
This risked promoting a one-sided, biological approach towards addiction which would have the ability 
to influence policy, although not necessarily always in a positive way. Another respondent believed that 
brain disease explanations could reduce efforts to address social factors that drive recruitment into 
drug addiction: 
 
“The problem I have with the medical model is that it basically lets politicians off the hook about doing 
anything in really disadvantaged environments and neighbourhoods. It becomes something that is still 
placed within an individual kind of perspective and doesn’t take an environmental, social or political 
context.” (Clinical Psychologist 1, female) 
 
While it may be an advantage of the BDM that addicted people are more willing to seek treatment, the 
concern was that they may have unrealistic expectations about treatment efficacy and limit the range of 
potential solutions. Addicted Individual’s Treatment Behaviour Neuroscientists and clinicians perceived 
a wide range of possible positive and negative effects of neuroscience models of addiction on addicted 
individuals. Some believed that the BDM can give addicted individuals insight about their condition and 
relieve associated guilt, thereby empowering them to seek treatment and change their behaviour. 
Others believed that its acceptance could produce learned helplessness and provide an excuse for not 
changing their behaviour. 
 
Facilitates Change: Potential Beneficial Impacts on Addicted Individuals Gain insight or Makes Sense of 
Their Condition  
 
Those with positive views of the BDM emphasised that knowledge of the BDM could give addicted 
individuals valuable “insight” into their condition and encourage them to “take it [their addiction and 
treatment] more seriously” (Clinical Psychologist 6, male)  
 
A neurobiological explanation of addiction could help addicted individuals make sense of their situation, 
as in “other medical disorders where there’s clear biological underpinnings” (Addiction Psychiatrist 1, 
male). It “helps people to understand medicine a little” and “makes them clear about what’s going on 
for them” (Addiction Psychiatrist 1, male). Another clinician said: 
 
“When I explain it, it’s like a penny drops; it’s like, ah, that makes so much sense now…that’s what’s 
really happening, that makes total sense.” (Addiction Physician 3, male) 
 
 
Relieving Guilt Participants also believed that an understanding of the BDM may reduce the guilt that 
addicted people often feel about their drug use. Accepting that addiction was a disease was seen as 
making the disorder “more acceptable” (Clinical Psychologist 4, female) and reducing perceived moral 
weakness. As one clinician remarked: 
 
“It means I’m not a bad person, or a weak person, I’m not morally bad; it means there have been 
changes in my brain.” (Addiction Physician 3, male) 
 
An animal researcher similarly remarked that: 
 
“[The BDM] is actually a very big relief to them and removes some of the self-punishment that goes 
along with being an addict.” (Animal Researcher 3, male) 
 
Motivating Treatment-Seeking Many interviewees believed that the BDM would motivate addicted 
individuals to seek treatment: 
 
“It will give people a reason to say, okay, there’s a defined reason why I’m an addict and therefore it’s 
treatable” (Animal Researcher 2, male) 
 
While respondents were critical of any treatment that was too focussed on medical approaches, they 
remained optimistic about the positive impact of the BDM in motivating addicted persons to seek help. 
 
“I think it creates a sense of hope, and optimism, so I think that what we can say to people is that we 
are adopting an approach that will maximise your likelihood of success.” (Clinical Psychologist 8, male) 
 
Empowering Many interviewees believed that the BDM may help addicted individuals to understand 
their behaviour and motivate behaviour change. 
 
“When they know that what’s going on in their brain as a result of taking drugs, and they know 
 
that when they are exposed to all the cues and triggers, that things happen in their brain that make it 
much harder for them to abstain from drugs. Having that understanding is empowering” (Animal 
Researcher 4, female) 
 
Clinicians provided examples of patients who reported that the BDM explanations had given them the 
strength to resist urges to use drugs: 
 
“I certainly know some clients have said that explanation really helped me and when I had an urge to 
drink I thought about that and it helped me; it sort of helped me delay the urge” (Addiction Physician 3, 
male) 
 
  
One addiction clinician described patients using brain scan images to represent what they were fighting 
to change. 
 
“We had a guy years ago who [asked for] … ‘a picture of the bit in my brain that lights up when I crave 
so I can put it up on the fridge door and know that’s my enemy.’ … It was a way of visualising for him 
the struggle that he was fighting … For him it was really empowering.” (Addiction Psychiatrist 2, male) 
 
 
Hindering Change: Potential Adverse Impacts on Addicted Individuals 
 
A significant minority of interviewees, including those who highlighted the positive impact of the BDM, 
also believed that neurobiological explanations could impede the recovery of addicted persons. 
 
Incurable and Learned Helplessness These experts believed that the BDM could foster a fatalistic 
attitude in affected persons that they were unable to control their life circumstances. “Disease” was 
seen as carrying a connotation that addiction was biological, allowing addicted persons to say “it’s all in 
my genes” (Psychologist 1, female) and that “the brain is responsible for the addiction” (Cognitive 
Neuroscientist 2, male). These interviewees believed that the BDM encouraged a sense of learned 
helplessness and the belief that one cannot change their behaviour: it’s a  “done deal” (Clinical 
Psychologist 5, female), and “a permanent condition” (Psychopharmacologist 2, male), or simply “my 
brain’s f**ked” (Clinical Psychologist 7, female).  
 
“Their own search for things, for information and for treatments can be completely shut down by this 
hearing from someone that it is a disease and you’re always going to have it and it gives them a sense of 
helplessness.” (Clinical Psychologist 4, female) 
 
They believed this would undermine addicted individuals’ beliefs in the effectiveness of treatment: 
 
“[I]t implies though that there’s no treatments or almost, that that’s it, that it’s a disease therefore, it’s 
just going to lead to deterioration and no light at the end of a tunnel. I think that, from a psychological 
point of view, that could potentially lead to learned helplessness.” (Clinical Psychologist 5, female) 
 
These respondents believed that while the BDM can encourage some people to enter treatment, it 
could reduce the motivation of others to seek treatment. 
 
Undermines Self-Control and Removes Responsibility Some participants believed that the BDM 
provided an excuse for drug use and undermined a sense of personal responsibility for it. 
 
“If it’s a brain disease that means that there’s something wrong with people’s brains which means that 
they take no personal responsibility for what’s happening to them and therefore that excuses their 
behaviour.” (Addiction Psychiatrist 1, male) 
 
Some felt that some addicted individuals found it attractive to believe that they lacked any control over 
their drug use. They gave examples of individuals who responded this way. 
 
“When I’ve tried to explain to [addicted participants] that this is not an absolute thing, that the changes 
we see in the brain don’t make it absolutely impossible to control, that’s sometimes met with resistance 
… ‘It’s not me that’s doing it, it’s my brain.’ That’s an attractive idea for people doing things which are 
either illicit or immoral.” (Cognitive Neuroscientist 1, male) 
 
One expert provided the following analogy: 
 
“Oh well I slept with this cocktail waitress because I have a sex addiction. It’s not because I’m naughty 
and because I could, because I was sick of my wife.” (Addiction Physician 2, male)Endorsement of the 
BDM of Addiction 
 
One third of the 31 subjects interviewed (n=10) strongly endorsed the BDM of addiction and they 
generally believed that it would have a predominantly positive impact upon addicted individuals and 
their treatment. 
 
“I think it’s overwhelmingly helpful, because people generally need some explanation that is reasonably 
scientifically based” (Human Neuropathologist 1, male) 
 
The remaining two-thirds (n=21) expressed more negative (n=7) or a combination of positive and 
negative views about the impact of the BDM (n =14). Seven believed that the model was flawed and 
that its impact would be predominantly negative: 
 
“It is fairly seriously flawed in all sorts of ways as a basic model. In particular it ignores all sorts of 
factors” (Psychologist 2, male) 
 
“I think it’s simplistic in the extreme” (Psychopharmacologist 2, male) 
 
Nearly half (n=14) held more mixed or ambivalent views, describing the BDM as a “double-edged 
sword” (Cognitive Neuroscientist 2, male). 
The clinicians were generally more sceptical than the neuroscientists about the BDM and its likely 
impact upon addicted individuals (See Fig. 1). Despite scepticism towards the BDM all but one of the 
clinicians reported making use of neuroscience explanations in treatment. When they did so they 
generally described the impact of chronic drug use on the brain:  
 
“They have to understand a very basic concept about neurotoxicity. What’s the drug doing to the 
brain?” (Behaviour Geneticist 1, female). 
 
 
Discussion 
 
This study assessed the perceived impacts of the brain disease model of addiction [11] among 
Australian addiction neuroscientists and clinicians. While our study indicated a preparedness within this 
group to explain addiction in terms of neurobiological changes brought on by drug use, their acceptance 
of the brain disease model was incomplete. This is consistent with previous studies of US clinicians and 
neuroscientists’ views on the geneticisation of smoking [36]. It is also consistent with findings of studies 
of the acceptance and impact of brain disease explanations on opioid dependent individuals receiving 
pharmaceutical treatment [6]. 
 
Many of the interviewees were receptive to the findings of neuroscience research on addiction but their 
  
opinions were more varied on whether this constituted a brain disease and the likely effects that the 
BDM would have on addicted individuals. Many believed the BDM could help addicted individuals to 
understand their own behaviour and may thereby facilitate behaviour change by: helping addicted 
people to gain insight into their condition; reducing guilt about their level of personal responsibility; and 
empowering them to seek treatment and resist drugs. The BDM was also seen as potentially reducing 
what many interviewees believed to be the damaging effects of moral views of addiction. The BDM was 
commonly spoken about as a useful rhetorical device for improving treatment of addiction and reducing 
the criminal punishment of individuals who needed treatment for their addiction. 
 
Fig. 1  Interviewees overall endorsement of the BDM of addiction 
 
 
 
This potential positive impact was seen to come at a cost however, with potential adverse impacts upon 
treatment and drug use for at least a subpopulation of addicted individuals. The most common concern 
was that it could hinder addicted individuals’ behaviour change, reduce their willingness to enter 
treatment, undermine their ability to reduce drug use, and provide them with an excuse for not 
attempting to change their behaviour. These results reflect the ambivalence within the literature, and 
consistent with a recent study of opioid dependent individuals receiving pharmacological treatment [6]. 
Despite high profile support for the BDM of addiction by leading US scientists and clinicians, less than 
one third of the Australian neuroscientists and clinicians in this study strongly endorsed the model. 
These results contrast with the recent consensus statement of the US based ASAM which declared that 
addiction is a brain disease [11]. 
 
The lack of strong support for the BDM of addiction in our study may reflect differing attitudes between 
neuroscientists and clinicians in Australia and the US. These nations have different approaches to drug 
policy: harm minimisation has long been a key part of Australian drug policy while abstinence and zero 
tolerance have been more marked in the US [37, 38]. Future research is needed to determine if our 
findings generalise to similar samples of experts in the US, UK, Europe, and Canada. 
 
Despite scepticism of the BDM of addiction, all but one of the clinicians we surveyed reported making 
some use of neuroscience explanations when treating addicted individuals. This probably reflects a 
more nuanced understanding of neuroscience research among clinicians who acknowledge the impact 
that chronic drug use has on brain and cognition but do not uncritically accept the strong form of the 
BDM advocated in the USA. These clinicians believed that neuroscience research could be useful in 
treating addicted individuals but that it must be used in ways that do not adversely affect treatment 
outcomes. Further research is required to determine when and how best to present neuroscience 
research to addicted patients. 
 
Limitations 
 
This study has a number of limitations. First, it is unlikely that the views of our sample will generalise to 
all staff involved in addiction treatment (e.g. counsellors, especially those who are recovering). It is also 
uncertain how our findings may apply to clinicians and researchers in other countries. 
Second, this study examined views about addiction in general, and did not investigate impacts of the 
BDM on persons with specific types of addiction. The majority of the clinicians we spoke to treated 
alcohol, opioid and psychostimulant addiction, and so our findings may reflect attitudes towards these 
addictions. Possible differences in the impact of the BDM on specific addictions, such as nicotine 
addiction and the behavioural addictions, need to be examined in subsequent studies. Interviews with 
members of the public, for example, suggest greater resistance to the brain disease view of nicotine 
than alcohol and opioid addiction [39, 40]. 
 
Third, all of the clinicians in our study were engaged in neuroscience research to some degree, which 
could have biased our sample’s responses. Pinto et al. [41] found that clinicians involved in research 
were more willing to use research findings in treatment and had a more positive view about their 
impact. Future research could use quantitative measures in a larger sample to compare level of 
endorsement of the BDM of those with a solely clinical background and those with a solely research 
background. 
 
Fourth, the views of clinicians and neuroscientists about the impact of the BDM on addicted patients 
may not coincide with the views and behaviour of addicted individuals. Research with addicted 
individuals is critical if we wish to understand how neuroscience affects addicted individuals’ beliefs 
about addiction, drug use and quitting [6]. 
 
 
Conclusion 
 
Despite promotion of the BDM of addiction in the USA by NIDA and ASAM, we found that only a 
minority of addiction neuroscientists and clinicians uncritically support a BDM of addiction. While most 
saw some value in neuroscience research on addiction, many were concerned about the potential 
adverse impacts of the BDM on addicted individuals’ motivation to enter treatment and recovery. There 
was a belief that the BDM of addiction may provide a rationale for addicted persons to seek treatment 
and reduce stigma that impedes treatmentseeking. Whether this belief transfers into practice is an 
empirical question. Public attitude studies suggest that the relationship may not be as straight forward 
as advocates of the BDM assume [42]. 
Neuroscience research, particularly brain imaging can be extremely seductive and persuasive. It may 
influence our expectations of the clinical effectiveness of treatments [43, 44], people’s self-perception 
[45], our judgment of facts [46, 47], and our understanding of moral decision-making [48]. Given this 
power, we should not assume that messages about “diseased brains” will always lead to increased 
treatmentseeking and reduced drug use. Messages about neuroscience research need to be tailored to 
individuals to foster better choices and health outcomes and avoid negative consequences. This 
requires information on how addicted individuals interpret this research. More research is needed to 
  
understand how addicted individuals understand and respond to neuroscience research of addiction, 
and how best to present this research to optimise treatment and reduce unintended adverse 
consequences. 
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